Royalty Pharma PLC

Royalty Pharma expands into Asia and secures a $250 M royalty‑backed note with Zymeworks to fund late‑stage antibody trials, boosting growth while preserving equity.

Royalty Pharma’s new Asia focus and high‑risk Zymeworks royalty‑loan reveal both growth upside and regulatory risk—an insider look at the firm’s strategic pivot.

Royalty Pharma’s short‑interest fell 50% in February, easing bearish pressure while the company gears up for a TD Cowen fireside chat to discuss strategy, reimbursement, and growth.

Royalty Pharma reports a 12.4 % jump in Q4 2025 net income to US$1.15 billion, driven by higher royalty income and lower expenses, while outlining FX‑hedging plans to safeguard FY‑2026 earnings.

Royalty Pharma reports strong Q4 2025 earnings near $210 M, driven by stable royalty portfolio and disciplined capital use, while FX risk shapes 2026 outlook.

Royalty Pharma’s $500 m partnership with Teva to fund TEV‑408—an anti‑IL‑15 antibody—could unlock high‑potential autoimmune therapies and boost RPL’s value while managing risk.

Royalty Pharma’s $275 million deal with Denali Therapeutics to fund Tividenofusp alfa shows how equity‑linked royalties can accelerate late‑stage biotech launches while sharing upside risk.

Royalty Pharma’s Q2 earnings report reveals a decline in income and valuation concerns, serving as a wake-up call for investors.

Royalty Pharma PLC reported mixed Q2 earnings, with revenue surging but profit declining, but raised its 2025 financial guidance despite the setback.

Royalty Pharma PLC reported strong revenue growth in the second quarter, driven by increased royalty receipts, and has raised its 2025 financial guidance.